Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer by Bauer, Katrina et al.
Bauer et al. BMC Cancer 2010, 10:228
http://www.biomedcentral.com/1471-2407/10/228
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Bauer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Use of ER/PR/HER2 subtypes in conjunction with 
the 2007 St Gallen Consensus Statement for early 
breast cancer
Katrina Bauer†1, Carol Parise†2 and Vincent Caggiano*†2
Abstract
Background: The 2007 St Gallen international expert consensus statement describes three risk categories and 
provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat 
primary breast cancer is recognized and used by clinicians worldwide. We now examine the variability of five-year 
survival of the 2007 St Gallen Risk Classifications utilizing the ER/PR/HER2 subtypes.
Methods: Using the population-based California Cancer Registry, 114,786 incident cases of Stages 1-3 invasive breast 
cancer diagnosed between 2000 and 2006 were identified. Cases were assigned to Low, Intermediate, or High Risk 
categories. Five-year-relative survival was computed for the three St Gallen risk categories and for the ER/PR/HER2 
subtypes for further differentiation.
Results and Discussion: There were 9,124 (13%) cases classified as Low Risk, 44,234 (65%) cases as Intermediate Risk, 
and 14,340 (21%) as High Risk. Within the Intermediate Risk group, 33,735 (76%) were node-negative (Intermediate Risk 
2) and 10,499 (24%) were node-positive (Intermediate Risk 3). For the High Risk group, 6,149 (43%) had 1 to 3 positive 
axillary lymph nodes (High Risk 4) and 8,191 (57%) had four or more positive lymph nodes (High Risk 5).
Using five-year relative survival as the principal criterion, we found the following: a) There was very little difference
between the Low Risk and Intermediate Risk categories; b) Use of the ER/PR/HER2 subtypes within the Intermediate
and High Risk categories separated each into a group with better five-year survival (ER-positive) and a group with
worse survival (ER-negative), irrespective of HER2-status; c) The heterogeneity of the High Risk category was most
evident when one examined the ER/PR/HER2 subtypes with four or more positive axillary lymph nodes; (d) HER2-
positivity did not always translate to worse survival, as noted when one compared the triple positive subtype (ER+/
PR+/HER2+) to the triple negative subtype (ER-/PR-/HER2-); and (e) ER-negativity appeared to be a stronger predictor
of poor survival than HER2-positivity.
Conclusion: The use of ER/PR/HER2 subtype highlights the marked heterogeneity of the Intermediate and High Risk 
categories of the 2007 St Gallen statements. The use of ER/PR/HER2 subtypes and correlation with molecular 
classification of breast cancer is recommended.
Background
The 2007 St Gallen international expert consensus state-
ment described three risk categories and provided rec-
ommendations for treatment of early breast cancer [1].
Since the first publication of the consensus statements in
1988 [2], now updated every two years, the set of recom-
mendations on how to best treat primary breast cancer is
recognized and used by clinicians worldwide.
Molecular classification is rapidly becoming the gold
standard for complete characterization of breast cancer
and the underlying technology has already led to genera-
tion of gene-profiling models to predict outcomes [3-5].
Despite these remarkable achievements, clinicians still
rely on traditional tumor marker analysis for treatment
decisions. We recently described the distribution and
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five-year survival of the subtypes of breast cancer based
on estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2)
[6,7], and found wide variation in survival especially
among the HER2-positive group of patients. We now
examine the variability of five-year survival of the 2007 St
Gallen Risk Classifications utilizing the ER/PR/HER2
subtypes.
Methods
Breast cancer cases used in these analyses were identified
using the population-based California Cancer Registry
(CCR). Cases are reported to the Cancer Surveillance
Sect io n of  t he  Ca li f ornia Depart m en t  of  P ubli c H ea l t h
from hospitals and any other facilities providing care or
therapy to cancer patients residing in California [8].
For the current study, we identified 114,786 first pri-
mary cases of invasive breast cancer (ICDO-3 sites
C50.0-C50.9) [9] diagnosed between January 1, 2000 and
December 31, 2006, and reported to the CCR as of
December 2008. This study period was selected because
it is prior to the era when trastuzumab was routinely
administered to women with early breast cancer that
overexpressed HER2. Cases diagnosed outside of Califor-
nia, at autopsy, or from death certificates were excluded.
The CCR requires the collection of tumor marker
information from the medical record on the status of ER
and PR for breast cancers diagnosed on or after January 1,
1990 and HER2 for breast cancers diagnosed on or after
January 1, 1999. ER and PR status are recorded according
to the pathologist's interpretation of assays. A tumor is
considered to be ER negative and PR negative if less than
5% of tumor cell nuclei are immunoperoxidase positive in
immunohistochemistry (IHC) assays. ER and PR status
m a y  a l s o  h a v e  b e e n  d e t e r m i n e d  b y  e x a m i n i n g  c y t o s o l
protein (ER negative or PR negative if there are fewer
than 3 or 5 fmol/mg of cytosol protein, respectively)
HER2 was assessed through IHC or fluorescence in situ
hybridization (FISH). IHC is scored on a qualitative scale
based on staining intensity: 0 and 1+ are negative, 2+ is
borderline, and 3+ is positive. FISH is scored on a quanti-
tative scale: less than 2 copies of the HER2 gene is nega-
tive and 2 or more copies is positive. Cases with complete
tumor marker data were used in this study and were cate-
gorized into one of the eight distinct subtypes based on
ER/PR/HER2 status of the tumor. Cases with unknown or
borderline tumor marker status were excluded from these
analyses [8].
Stage at diagnosis was collected from the patient's med-
ical record and coded according to the American Joint
Commission on Cancer (AJCC) Cancer Staging Manual
6th edition [10]. The CCR collected Surveillance Epidemi-
ology and End Results (SEER) Extent of Disease (EOD)
for breast cancer cases diagnosed from 1988 through
December 2003 [11], and in 2004, began collecting Col-
laborative Staging data items [12]. EOD was converted to
AJCC stage at diagnosis using SEER guidelines [13]. For
these analyses, stage IV and cases with unknown stage
were omitted. Tumor grade was collected from the medi-
cal record and coded according to ICDO-3 [9].
Treatment information available from the registry
abstract was recorded as one of four possibilities: a) che-
motherapy without endocrine therapy; b) endocrine ther-
apy without chemotherapy; c) chemotherapy and
endocrine therapy; d) no chemotherapy or endocrine
therapy or unknown. Information about the use of spe-
cific anti-HER2 therapy was not available.
Cases were assigned to Low, Intermediate, or High Risk
categories according to published criteria [1] with one
exception. The extent of peritumoral vascular invasion
was not available from the CCR's database and could not
be utilized for determining the St Gallen risk stratifica-
tion.
Counts and 5-year relative cumulative survival were
calculated using SEER*Stat 6.1.4. The actuarial method
was used for relative survival calculations. Five-year-rela-
tive survival was computed for the three St Gallen risk
categories, and also for the ER/PR/HER2 subtypes to fur-
ther differentiate the risk categories. Differences between
survival curves were compared using the Z- test for com-
parison of relative survival rates [14].
Results
There were 114,786 incident cases of Stages 1-3 invasive
breast cancer diagnosed between 2000 and 2006. After
exclusion of 38,418 cases with at least one missing tumor
marker there were 76,368 cases. An additional 8,670 were
eliminated because they lacked age, size of tumor, stage,
or grade resulting in 67,698 (59%) cases available for sur-
vival analysis (Table 1). Table 2 shows the clinicopatho-
logic breakdown of the cases included in the analysis.
The distribution of the ER/PR/HER2 subtypes within
each risk category is shown in Table 3 and Figure 1. There
were 9,124 (13%) cases classified as Low Risk, 44,234
(65%) cases as Intermediate Risk, and 14,340 (21%) as
High Risk. Within the Intermediate Risk group, 33,735
Table 1: Summary of cases included in the analysis.
Cases with stages 1-3 1st 
primary invasive breast 
cancer 2000-2006
114,786
Cases missing at least one 
tumor marker
38,418
Cases missing age, tumor 
size, stage, or grade
8,670
Total included in the 
analysis
67,698Bauer et al. BMC Cancer 2010, 10:228
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Table 2: Demographic and clinicopathologic characteristics for stages 1-3 first primary invasive breast cancer, 2000-2006.
n %
Node Status
Node Negative 42,859 63.3%
1-3 Nodes Positive 16,648 24.6%
>3 Nodes Positive 8,191 12.1%
Stage
I 31,721 46.9%
II 28,952 42.8%
III 7,025 10.4%
Grade
Well differentiated; Grade I 14,813 21.9%
Moderately differentiated; Grade II 28,406 42.0%
Poorly differentiated; Grade III 23,191 34.3%
Undifferentiated; anaplastic; Grade IV 1,288 1.9%
ER/PR/HER2 Status
+/+/+ 7,343 10.8%
+/+/- 36,906 54.5%
+/-/+ 2,258 3.3%
+/-/- 6,305 9.3%
-/+/+ 319 0.5%
-/-/+ 4,805 7.1%
-/+/- 652 1.0%
-/-/- 9,110 13.5%
Tumor Size
≤2 cm 42,043 62.1%
> 2 cm 25,655 37.9%
Race/Ethnicity
Non-Hispanic White 47,016 69.4%
Non-Hispanic Black 3,606 5.3%
Hispanic 10,134 15.0%
Asian/Pacific Islander 6,942 10.3%
Age
≤45 11,755 17.4%
46-69 40,058 59.2%
≥70 15,885 23.5%
Total 67,698Bauer et al. BMC Cancer 2010, 10:228
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(76%) were node-negative (Intermediate Risk 2) and
10,499 (24%) were node-positive (Intermediate Risk 3).
For the High Risk group, 6,149 (43%) had 1 to 3 positive
axillary lymph nodes (High Risk 4) and 8,191 (57%) had
four or more positive lymph nodes (High Risk 5).
Five-year relative survival curves revealed a statistically
significant difference between the Low and both Interme-
diate Risk categories (p < 0.001) (Figure 2). There was no
statistically significant difference between the two Inter-
mediate risk categories. The High Risk category is clearly
separated from the Low and Intermediate Risk catego-
ries, and those with four or more positive lymph nodes
(High Risk 5) have worse survival than those with 1 to 3
positive lymph nodes (High Risk 4) (p < 0.001).
When the St Gallen Risk categories were analyzed
according to ER/PR/HER2 subtypes, no difference in sur-
vival was seen in the Low Risk group (not shown) but dis-
tinct differences were noted in the Intermediate Risk
(Figure 3) and High Risk (Figure 4) categories. All ER-
positive subtypes within the Intermediate Risk group,
regardless of HER2 status, had excellent five-year relative
survival (95% or better), whereas all ER-negative subtypes
had worse survival.
For the High Risk group, a similar ER-positive pattern
was noted except for the ER+/PR-/HER2- subtype. When
the Intermediate and High Risk categories were analyzed
according to axillary lymph node status as well as ER/PR/
HER2 status, the ER+/PR-/HER2+ and ER+/PR-/HER2-
subtypes had equally excellent five-year relative survival
within the node-negative group (Intermediate Risk 2) (p
= 0.234), and the ER+/PR+/HER2- and ER+/PR-/HER2-
subtypes had significantly better survival than the ER-/
PR+/HER2- subtype within the node-positive group
(Intermediate Risk 3), as seen in Figures 5 and 6 (p <
0.001 for both comparisons).
Within the High Risk category characterized by 1 to 3
positive nodes (High Risk 4), the ER+/PR+/HER2+ and
ER+/PR-/HER2+ subtypes had excellent five-year sur-
vival whereas the remaining subtypes, all ER-negative,
had significantly worse survival (p < 0.02) (Figure 7). For
t h o s e  H i g h  R i s k  p a t i e n t s  w i t h  f o u r  o r  m o r e  p o s i t i v e
lymph nodes (High Risk 5), the best survival was seen in
the ER+/PR+/HER2+ subtype and the worst survival in
the ER-/PR-/HER2- subtype (Figure 8) (p < 0.001).
Treatment information is summarized in Table 4. Of
the 4,717 cases within the Low Risk category known to
have received some form of therapy, 4,019 (85%) received
only endocrine treatment (ET) and 698 (7%) received
chemotherapy and ET. For the Intermediate Risk cate-
gory, 18,908 (66%) received chemotherapy with or with-
out ET, and 9,629 (34%) received only ET. Within the
High Risk category, 11,016 (94%) received chemotherapy
with or without ET, and 671 (6%) received only ET.
Discussion
Clinicians have a variety of resources and guidelines to
assist in treatment decisions for early breast cancer
patients [15]. Adjuvant! Online [16], the guidelines of the
National Comprehensive Cancer Network [17], the 21-
gene recurrence score [4], and the 70-gene expression
assay [3], are well-known to most oncologists. The St
Gallen Consensus Statements, however, remain a valu-
able tool, especially in Europe, perhaps because of its sim-
plicity and ease of risk determination. Successive St
Gallen conferences since 1988 have produced treatment
guidance based on available evidence and expert opinion
for the therapy of early breast cancer patients outside
clinical trials. Various iterations of the St Gallen Consen-
sus recommendations have been validated and compli-
ance with recommendations for systemic therapy has
Table 3: Distribution of the ER/PR/HER2 subtypes by St Gallen risk category.
Low Risk Intermediate
Risk 2
Intermediate
Risk 3
High Risk
4
High Risk
5
n%
+/+/+ 0 4,242 0 1,965 1,136 7,343 10.8
+/+/- 7,841 16,456 8,912 0 3,697 36,906 54.5
+/-/+ 0 1,244 0 652 362 2,258 3.3
+/-/- 1,228 2,908 1,437 0 732 6,305 9.3
-/+/+ 01 7 6 0 8 4 5 9 319 0.5
-/-/+ 0 2,544 0 1,279 982 4,805 7.1
-/+/- 55 369 150 0 78 652 1.0
-/-/- 0 5,796 0 2,169 1,145 9,110 13.5
n 9,124 33,735 10,499 6,149 8,191 67,698
% 13.5 49.8 15.5 9.1 12.1Bauer et al. BMC Cancer 2010, 10:228
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been shown to improve survival of women with node-
negative breast cancer, refinements have been suggested
[18-24] and some shortcomings have been described
[25,26].
Our initial CCR investigations of triple negative breast
cancer [27,28] prompted us to examine all newly diag-
nosed breast cancer patients using ER/PR/HER2 subtype
as a surrogate for the molecular classification [6,7]. We
w e r e  s t ru c k  b y  t h e  wi d e  va ri a t i o n  i n  fi v e -y e a r  s u rvi va l
based on ER/PR/HER2, the marked heterogeneity of
HER2-positive cancers, and the excellent survival of
patients with ER-positive cancers irrespective of HER2
status. Indeed, we found the ER-positive/PR-positive/
HER2-positive subset of patients to have a five-year rela-
tive survival of 91.3% whereas the ER-negative/PR-nega-
tive/HER2-positive subset to have a 75.9% survival [7].
Clearly, not all HER2-positive breast cancers are bad
actors. We therefore decided to explore this more fully
and determine the ER/PR/HER2 subtypes within the con-
text of the St Gallen risk categories.
The Intermediate Risk is the largest of the three risk
categories defined in the 2007 St Gallen statement, con-
stituting 65.3% of all patients, the Low Risk the smallest
(13.4%) and the High Risk next at 21.3%. Based solely on
five-year relative survival, there is not much difference
between Low and Intermediate Risk, but clear separation
of the High Risk category is noted.
Use of the ER/PR/HER2 subtypes clearly separates the
Intermediate Risk category into two distinct groups, one
with better five-year survival (all ER-positive) and one
with worse survival (all ER-negative). This separation
persists for the node-negative subgroup (Intermediate
Risk 2) as well as the node-positive subgroup (Intermedi-
ate Risk 3), although in this latter subgroup the ER-/PR+/
HER2- subtype is rather small. The existence of the ER-/
PR+ subtypes is controversial [29,30] although some
Figure 1 Stratification of the ER/PR/HER2 subtypes within the St Gallen risk categories.Bauer et al. BMC Cancer 2010, 10:228
http://www.biomedcentral.com/1471-2407/10/228
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Figure 2 Five-year relative survival of low, intermediate, and high risk St Gallen categories for first primary invasive breast cancers in Cal-
ifornia, 2000-2006.
Figure 3 Five-year relative survival for all cases within the St Gallen intermediate risk group according to the ER/PR/HER2 subtypes.Bauer et al. BMC Cancer 2010, 10:228
http://www.biomedcentral.com/1471-2407/10/228
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Figure 4 Five-year relative survival for all cases within the St Gallen high risk group according to the ER/PR/HER2 subtypes.
Figure 5 Five-year relative survival for node-negative cases within the St Gallen intermediate risk group (intermediate risk 2) according to 
the ER/PR/HER2 subtypes.
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believe it is a distinctive subtype with a poor prognosis
[31]. Our results, while not definitive in any sense, would
tend to agree with this latter interpretation.
Marked variation in five-year survival is noted within
the High Risk category, both for the subgroups with 1-3
positive axillary lymph nodes (High Risk 4) and >3 posi-
tive axillary lymph nodes (High Risk 5). The widest varia-
tion in five-year survival is seen for this latter subgroup,
ranging from the triple positive subtype (ER+/PR+/
HER2+) at 83% to the triple negative subtype (ER-/PR-/
HER2-) at 48%. Clearly, there are different levels of risk.
Once again, ER-positive subtypes have better survival
than ER-negative subtypes, regardless of HER2 status.
That the 2007 St Gallen risk categories are useful for
therapy guidance is evident from the limited treatment
analysis, with 85% within Low Risk category receiving
o n l y  E T ,  a n d  9 4 %  wi t h i n  H i g h  Ris k  ca t e g o ry  r ec e i vi n g
chemotherapy with or without ET. However, our study
has shown that, using five-year relative survival as the
single principal criterion, (a) there is very little difference
between Low Risk and Intermediate Risk categories, (b)
use of the ER/PR/HER2 subtypes within the Intermediate
and High Risk categories separates each into a group with
better five-year survival (ER-positive) and a group with
worse survival (ER-negative), irrespective of HER2-sta-
tus, (c) the heterogeneity of the High Risk category is
most evident when one examines the ER/PR/HER2 sub-
types with four or more positive axillary lymph nodes, (d)
HER2-positivity, per se, does not always translate to a
worse survival, as noted when one compares the triple
positive subtype (ER+/PR+/HER2+) to the triple negative
subtype (ER-/PR-/HER2-), and (e) ER-negativity appears
to be a stronger predictor of poor survival than HER2-
positivity.
The 2009 St Gallen conference proposed "a radically
different treatment selection algorithm for the manage-
ment of early breast cancer" and abandoned the three risk
categories [32]. Instead, the threshold for indication of
each systemic treatment modality was outlined, and two
situations were recognized in which the decision to use
adjuvant chemotherapy was relatively clear-cut, i.e., for
patients with triple negative breast cancer and for
patients with HER2-positive breast cancer. The present
study once again confirms the poor survival of the triple
negative subtype and the heterogeneity of the HER2-pos-
itive group of patients [7,27]. Although combined endo-
crine therapy in addition to anti-HER2 therapy without
chemotherapy in strongly ER-positive, HER2-positive
patients is logical but unproven [32], our survival results
for the HER2-positive subtypes within the Intermediate
and High Risk categories suggest an opportunity for just
such a randomized clinical trial utilizing traditional clini-
Figure 6 Five-year relative survival for node-positive cases within the St Gallen intermediate risk group (intermediate risk 3) according to 
the ER/PR/HER2 subtypes.Bauer et al. BMC Cancer 2010, 10:228
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copathological factors, tumor markers, and gene expres-
sion profiling assays.
In a departure from the previous conference, the panel
of the 2009 St Gallen meeting also supported the use of a
validated multigene-profiling assay, if readily available, as
an adjunct to high quality phenotyping of breast cancer in
cases in which the indication for adjuvant chemotherapy
remains uncertain. We are in agreement with this recom-
mendation, and further urge use of the ER/PR/HER2 sub-
type or phenotype expression as a surrogate, albeit
imperfect, for the molecular classification of breast can-
cer [33,34]. Correlation of the ER/PR/HER2 subtypes
with gene-profiling assays makes good clinical sense. We
suggest avoidance of the phrase "ER and/or PR positive".
Although we studied a large, racially diverse group of
breast cancer patients, we recognize the limitations of
this type of population-based registry investigation. His-
tologic grading of tumors, as well as tests for ER, PR, and
HER2 were performed by a wide variety of laboratories
without central review. Only 59% of the original cohort of
patients was found to have complete clinicopathological
factors. Of the 38,418 cases found lacking at least one
tumor marker, the majority (86%) were missing HER2.
The exclusion of subjects without ER or PR results has
been noted in other population-based cancer registry
studies and our findings are similar [35-37]. Missing
HER2 results have been described in our previous publi-
cations [27,28]. The St Gallen risk categories were applied
retrospectively. Peritumoral vascular invasion was not
recorded in the cancer registry abstract and could not be
used for determination of the St Gallen risk categories. It
is not entirely clear how this affects the risk categories. In
a recent study, the adverse prognostic impact of peritu-
moral vascular invasion was limited to receptor-negative
tumors regardless of chemotherapy [38]. Lastly, treat-
ment information was minimal and generic in nature. Of
the subjects known to have received some form of adju-
vant therapy, the majority of ER-positive and ER-negative
patients received endocrine therapy and chemotherapy,
respectively. However, start and stop dates of treatments,
and the specific forms of endocrine and chemotherapy
were not available in the registry data. Anti-HER2 ther-
apy was not recorded in the registry abstract. It should be
noted that, in the United States, trastuzumab was
approved for adjuvant treatment of breast cancer patients
in November 2006, and thus the lack of anti-HER2 treat-
ment data may have only a slight confounding effect.
Lastly, patient accrual was from 2000 to 2006 and ana-
Figure 7 Five-year relative survival for node positive cases with 1-3 lymph nodes within the St Gallen high risk group (high risk 4) according 
to the ER/PR/HER2 subtypes.Bauer et al. BMC Cancer 2010, 10:228
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lyzed as of December 2008. We recognize that many
patients were only at risk for two years and that many low
risk patients may relapse after five years. Continued fol-
low-up and analysis is planned.
Despite these shortcomings, we believe our study is of
value because of the large number of breast cancer
patients examined, reflecting real-world experience of a
statewide cancer registry in an ethnically diverse popula-
tion. We have shown how the use of ER/PR/HER2 sub-
type or phenotype expression highlights the marked
heterogeneity of the Intermediate and High Risk catego-
ries of the 2007 St Gallen statements. We welcome the
use of the molecular classification of breast cancer and
gene-profiling assays. Further, we believe it is prudent to
correlate molecular findings with less expensive tech-
niques such as the use of ER/PR/HER2 subtypes and
immunohistochemical (IHC) profiles, the so-called "Poor
Man's IHC definitions of microarray-based intrinsic sub-
types" [34].
Conclusion
The use of ER/PR/HER2 subtype highlights the marked
heterogeneity of the Intermediate and High Risk catego-
ries of the 2007 St Gallen statements. The use of ER/PR/
HER2 subtypes and correlation with molecular classifica-
tion of breast cancer is recommended.
Figure 8 Five-year relative survival for node positive cases with >3 lymph nodes within the St Gallen high risk group (high risk 5) according 
to the ER/PR/HER2 subtypes.
Table 4: Differences in use of chemotherapy and endocrine therapy (ET) among the St Gallen risk categories.
Low Intermediate High
Chemotherapy without ET 349 12,429 8,007
ET without chemotherapy 4,019 9,629 671
Chemotherapy + ET 349 6,479 3,009
None or Unknown 4,407 15,697 2,653
Total 9,124 44,234 14,340Bauer et al. BMC Cancer 2010, 10:228
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